December Global Macro Monthly & Investment Strategy - Covid 19: It’s behind you… Oh no it isn’t
- The pandemic dominates the short run outlook. In the Eurozone and UK, cases remain elevated and restrictions could rise anew. In the US, this process is underway as cases set new records. Both threaten winter weakness
- A vaccine offers hope for 2021. Restrictions could be eased as the vulnerable are inoculated. Mass vaccination should spur growth more materially.
- Rising global trade has boosted some economies, including China and Germany. While renewed virus cases threaten another demand dip, the vaccine poses some threat if consumers rotate to long-denied services.
- Policy remains supportive. The Euro area agreed on its fiscal programme. The US looks set to pass further short-term emergency stimulus. Central banks remain committed to ongoing accommodative policy, with the ECB the latest to extend its policy easing, now through to 2022.
This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.
It has been established on the basis of data, projections, forecasts, anticipations and hypothesis which are subjective. Its analysis and conclusions are the expression of an opinion, based on available data at a specific date. All information in this document is established on data made public by official providers of economic and market statistics. AXA Investment Managers disclaims any and all liability relating to a decision based on or for reliance on this document. All exhibits included in this document, unless stated otherwise, are as of the publication date of this document. Furthermore, due to the subjective nature of these opinions and analysis, these data, projections, forecasts, anticipations, hypothesis, etc. are not necessary used or followed by AXA IM’s portfolio management teams or its affiliates, who may act based on their own opinions. Any reproduction of this information, in whole or in part is, unless otherwise authorised by AXA IM, prohibited.
This document has been edited by AXA INVESTMENT MANAGERS SA, a company incorporated under the laws of France, having its registered office located at Tour Majunga, 6 place de la Pyramide, 92800 Puteaux, registered with the Nanterre Trade and Companies Register under number 393 051 826. In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.
In the UK, this document is intended exclusively for professional investors, as defined in Annex II to the Markets in Financial Instruments Directive 2014/65/EU (“MiFID”). Circulation must be restricted accordingly.
© AXA Investment Managers 2020. All rights reserved